Answers are grounded in this paper and cite their sources.
Background Metabolic acidosis is linked to faster kidney function decline in children with CKD, especially in those with glomerular CKD who are more likely to have untreated acidosis. Unlike prior cohorts limited to children with established CKD, our cohort consisted of 786 children with glomerular disease and largely preserved kidney function at enrollment. We studied the prevalence, factors associated with acidosis, and the impact of unresolved acidosis on eGFR decline. Methods Children aged 1-17 years from NEPTUNE or CureGN were included. Acidosis was defined as serum bicarbonate <22 mEq/L. Unresolved acidosis was defined as acidosis at baseline that remained <22 mEq/L, and resolved acidosis was defined as baseline acidosis that reached ≥22 mEq/L on follow-up. Associations of acidosis with demographic and clinical characteristics were assessed. The primary outcome eGFR slope (ml/min/1.73m 2 /year) was analyzed using an adjusted linear mixed-effects model. Secondary analysis examined associations of acidosis with interstitial fibrosis and tubular atrophy (IFTA). Results Mean baseline serum bicarbonate was 24.8±3.2 mEq/L and median eGFR was 97 ml/min/1.73m 2 (IQR: 81, 117). The prevalence of acidosis was 12% (n=96), and only 4% of children with acidosis were receiving alkali therapy at baseline. Children with unresolved acidosis had a greater decline in eGFR compared to those with resolved acidosis, with a difference in eGFR slope of -4.05 ml/min/1.73m 2 /year (95%CI: -5.62, -2.47), independent of disease diagnosis and proteinuria. The degree of IFTA was not significantly associated with categories of serum bicarbonate (P = 0.61). Conclusions Unresolved metabolic acidosis was associated with a faster eGFR decline in children with glomerular disease. Acidosis was not associated with baseline IFTA, suggesting it may not simply reflect pre-existing fibrosis. Further studies are needed to clarify mechanisms linking metabolic acidosis with kidney disease progression and to identify patients who may benefit from targeted interventions.
No takes yet. Share an insight, caveat, or question.
Kilduff et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: